13-05-2025
Immunome (IMNM) Receives a Buy from TD Cowen
TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Immunome (IMNM – Research Report) today. The company's shares closed today at $7.94.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Van Buren covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Regeneron, and Moderna. According to TipRanks, Van Buren has an average return of -6.3% and a 35.20% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immunome with a $27.00 average price target.
IMNM market cap is currently $649.1M and has a P/E ratio of -1.44.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IMNM in relation to earlier this year. Most recently, in March 2025, Jean Jacques Bienaime, a Director at IMNM bought 7,800.00 shares for a total of $60,684.00.
